This comparative perspective juxtaposes the two compounds with respect to molecular pharmacology, clinical efficacy, safety, and potential clinical positioning, and proposes that, because resmetirom primarily targets hepatic lipid disposal whereas semaglutide unloads systemic caloric pressure, their complementary actions could be harnessed sequentially or in combination to achieve broader, more durable disease modification across the heterogeneous spectrum of patients with MASH
Assess your symptoms online for free Sign up to the Patient newsletter Your weekly dose of clear, trustworthy health advice - written to help you feel informed, confident and in control
Learn the science behind Wegovy's active ingredient, semaglutide and how it compares to other weight loss treatments
More serious complications require immediate medical attention and occur in less than certain patients
Low levels should alert to the possibility of adrenal insufficiency